Epidemiologic Field Studies

BCDDP：乳腺癌检测示范项目随访研究（1030）这项研究跟踪了大约60，000名乳腺癌示范项目（BCDDP）的前参与者。目前的分析包括：1）子宫切除术状态和全因及原因特异性死亡率; 2）涉及乳腺癌、结肠癌、卵巢癌和肾癌的饮食汇总项目分析; 3）众多DCEG队列汇总项目。胃癌：山东临朐抑制胃癌前病变的随机多干预试验（446）我们在中国农村进行了一项为期8年的试验，结束后收集了7年的额外随访数据，以确定三种治疗方法中的任何一种是否会影响胃癌的发病率或特定的死亡原因。治疗是长期的维生素（C，E和硒）补充剂和大蒜补充剂，从1995年到2003年，并在1995年给予阿莫西林/奥美拉唑一次。一篇正在修订的论文显示，阿莫西林/奥美拉唑治疗在14年内降低了胃癌的发病率。炎症性乳腺癌（IBC）初步研究和病例对照研究（314）本病例对照研究将纳入北非4个中心（突尼斯1个中心加几家私人诊所，埃及2个中心，摩洛哥2个中心）5年内累积的约400例IBC病例。纳入两个对照组：1）400例非IBC乳腺癌病例; 2）400例访问者对照（不包括一级亲属），随机选择研究医院的女性住院患者（不包括乳腺癌、卵巢癌、子宫内膜癌和鼻咽癌患者）。该研究包括问卷调查，人体测量，唾液/颊细胞收集，IBC病例乳房的数字照片，以及在选定中心收集IBC病例和非IBC乳腺癌对照的石蜡包埋肿瘤组织。这项研究是与密歇根大学合作进行的，表格的开发和翻译由美国国家癌症研究所协调。NCI-DCEG负责在埃及、突尼斯和摩洛哥的研究中心制定研究程序。埃及于2009年3月、突尼斯于2009年8月、摩洛哥于2011年1月开始收集数据。

BCDDP: Breast cancer detection demonstration project follow-up study (1030) This study follows about 60,000 former participants in the Breast Cancer Demonstration Project (BCDDP). Current analyses include: 1) hysterectomy status and all-cause and cause-specific mortality; 2) dietary pooling project analyses involving cancers of the breast, colon, ovary, and kidney; and 3) numerous DCEG cohort pooling projects. Gastric cancer: Randomized multi-intervention trial to inhibit precancerous gastric lesions in Linqu, Shandong Province (446) We gathered additional follow-up data for seven years following the end of an 8-year trial in rural China to determine whether any of three treatments would affect gastric cancer incidence or specific causes of mortality. The treatments were long-term vitamin (C, E, and selenium) supplementation and garlic supplementation, given from 1995 to 2003, and one time administration of amoxicillin/omeprazole given in 1995. A paper is in revision showing that amoxicillin/omeprazole treatment reduced gastric cancer incidence over a fourteen year period. Inflammatory breast cancer (IBC) pilot study and case-control study (314) This case-control study will include approximately 400 IBC cases accrued over a five-year period at 4 centers in North Africa (1 center in Tunisia plus several private clinics, 2 in Egypt, and 2 in Morocco). Two control groups are being included: 1) 400 non-IBC breast cancer cases and; 2) 400 visitor controls (excluding first-degree relatives) to randomly selected female inpatients (excluding those with breast, ovarian, endometrial, and nasopharyngeal cancer) in the study hospitals. The study involves the administration of a questionnaire, anthropometric measurements, Saliva/Buccal Cells collection, digital photographs of the breasts of IBC cases, and the collection of paraffin-embedded tumor tissue for IBC cases and non-IBC breast cancer controls at selected centers. The study is being conducted as a consortium with the University of Michigan, with forms development and translation coordinated at the National Cancer Institute-USA. The NCI-DCEG is responsible for developing study procedures at the study centers in Egypt, Tunisia, and Morocco. Data collection began in March 2009 in Egypt, August 2009 in Tunisia, and January 2011 in Morocco.